On (b)(6) 2022 during follow-up, fresenius became aware this patient with end stage renal disease (esrd) on continuous cyclic peritoneal dialysis [cc(pd)] for renal replacement therapy (rrt) underwent surgery (specifics not provided) on (b)(6) 2022 due to drain pain and drain complications.Follow-up with the patient's pd registered nurse (pdrn) revealed the patient's pd catheter (not a fresenius product) was surgically placed on (b)(6) 2022 without reported issue.The patient began experiencing drain complications later the same month and was sent to the surgeon on (b)(6) 2022 for evaluation.The surgeon felt the pd catheter may have migrated out of position, and the patient was scheduled for exploratory pd catheter surgery on (b)(6) 2022.During surgery it was discovered the patient had several adhesions which were obstructing the flow of solution.The surgeon repositioned the tip of the pd catheter with good success, and the patient resumed ccpd therapy the same evening without issue.The patient continues to undergo ccpd therapy utilizing the same liberty select cycler and has recovered from the events.The pdrn reported the events were unrelated to the patient's utilization of any fresenius product(s) and/or device(s).It was reported the adhesions were a complication of the initial pd catheter placement.(b)(4).This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|